WuXi Biologics Signs Service Agreement with Sino Biopharm for mAb Discovery

• WuXi Biologics has entered into a service agreement with Sino Biopharm to discover a first-in-class monoclonal antibody (mAb) using WuXi’s integrated discovery platforms.

• The agreement grants Sino Biopharm exclusive rights to the mAb, with WuXi Biologics supporting the project through antibody generation, optimization, and developability assessment.

WuXi Biologics has announced a new service agreement with Sino Biopharm to discover a first-in-class monoclonal antibody (mAb) against an undisclosed target. The collaboration, unveiled on December 30, 2024, marks a key milestone in Sino Biopharm’s internationalization strategy and underscores WuXi Biologics’ strength as a global Contract Research, Development, and Manufacturing Organization (CRDMO).

Under the agreement, WuXi Biologics will leverage its advanced discovery technology platforms, including single B cell technology, to support Sino Biopharm in identifying and optimizing a preclinical mAb candidate. Sino Biopharm will hold exclusive rights to the mAb and will be responsible for the subsequent Investigational New Drug (IND) applications, clinical trials, and commercialization.

Dr. Chris Chen, CEO of WuXi Biologics, commented, “We’re delighted to provide our proven integrated discovery platforms for Sino Biopharm to discover a first-in-class mAb. This agreement further reinforces the value of R (research) in our unique CRDMO model and highlights WuXi Bio’s role as the partner of choice in discovery services, including Chinese pharmaceutical companies in building innovative pipelines.”

In turn, Mr. Tse, Eric S Y, CEO of Sino Biopharm, expressed enthusiasm for the collaboration, stating, “We are extremely delighted to have reached a service agreement with WuXi Biologics, leveraging its comprehensive and streamlined suite of solutions for biologic discovery.” He emphasized the partnership’s potential to accelerate the development of innovative treatments for patients globally.